A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: Clinicopathologic analysis, molecular features, and possible pitfalls in routine practice

Journal of Thoracic Oncology

Volumn 5, Issue 6, 2010, Pages 830-836

  Casali, Christian ^a   Rossi, Giulio ^a   Marchioni, Alessandro ^b   Sartori, Giuliana ^a   Maselli, Federica ^c   Longo, Lucia ^d   Tallarico, Emilia ^a   Morandi, Uliano ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c PATHOLOGY UNIT   (Italy)

^d AUSL Modena   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; ERBB2 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; LUNG SURGERY; MALE; MEDICAL PRACTICE; MOLECULAR DYNAMICS; MUCINOUS CARCINOMA; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; WORLD HEALTH ORGANIZATION; ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; VERY ELDERLY;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 77953173422     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d60ff5     Document Type: Article

References (26)

1. Travis WD, Brambilla E, Muller-Hermelink HK, et al. (Eds.) Tumours of the Lung, Pleura, Thymus and Heart. Pathology and Genetics. WHO Classification of Tumours. Lyon: IARC Press; 2004.
2. Zell JA, Ou SHI, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005;23:8396-8405.
3. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer 1995;75:2844-2852.
4. Sakao Y, Miyamoto H, Sakuraba M, et al. Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of nonbronchioloalveolar carcinoma components. Ann Thorac Surg 2007;83:209-214.
5. Sakurai H, Dobashi Y, Mizutani E, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004;78:1728-1733.
6. Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components. Am J Surg Pathol 2003;27:937-951.
7. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346. (Pubitemid 40425952)
8. Wu CC, Hsu HY, Liu HP, et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 2008;113:3199-3208.
9. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
10. Sartori G, Cavazza A, Sgambato A, et al. EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. Am J Clin Pathol 2009;131:478-489.
11. Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol 2003;4:45-55.
12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
13. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. Plos Med 2005;2: e17-e21.
14. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-790.
15. Hishida T, Nagai K, Yokose T, et al. Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? J Thorac Cardiovasc Surg 2006;131:838-842.
16. Suzuki K, Koike T, Shibusa T. Evaluation of radiologic diagnosis in peripheral clinical IA lung cancer-a prospective study for radiological diagnosis of peripheral early lung cancer (JCOG 0201). J Clin Oncol 2006;24:419s.
17. Breathnach OS, Kwiatkowski DJ, Finkelstein DM, et al. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg 2001;121:42-47.
18. Roberts PF, Straznicka M, Lara PN, et al. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg 2003;126:1597-1602.
19. Wislez M, Massiani MA, Milleron B, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest 2003;123:1868-1877.
20. Travis WD, Brambilla E, Masayuki N, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. 13th World Conference on Lung Cancer. J Thorac Oncol 2009;4(suppl 1):S86-S89.
21. Copin MC, Buisine MP, Leteurtre E, et al. Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum Pathol 2001;32:274-281.
22. Marchetti A, Buttitta F, Pellegrini S, et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 1996;179:254-259.
23. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutations and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007;9:320-326.
24. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in nonsmall-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-865.
25. Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 2005;128:317-321.
26. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008;32:810-827.